US Patent 11154549 Opioid compositions resistant to overdose and abuse
Patent 11154549 was granted and assigned to Elysium Therapeutics, Inc. on October, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+557 characters)
Article
Patent abstract
The invention provides pharmaceutical compositions comprising macromolecular gastrointestinal enzyme-labile opioid prodrugs, co-formulated with small-molecule and/or macromolecular gastrointestinal enzyme inhibitors. The macromolecular constructs are minimally absorbed from the GI tract, and can produce non-linear pharmacokinetic profiles of the delivered opioid agonist following oral ingestion. An optional macromolecular opioid antagonist may also be present in compositions of the invention to discourage tampering by potential abusers.
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 30 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111545490
Date of Patent
October 26, 2021
0Patent Application Number
201904170
Date Filed
April 17, 2019
0Official Website
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111545490
Date of Patent
October 26, 2021
0Patent Application Number
201904170
Date Filed
April 17, 2019
0Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 27 Oct, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11154549 Opioid compositions resistant to overdose and abuse
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11154549
Date of patent
October 26, 2021
Patent application number
20190417
Date Filed
April 17, 2019
Find more entities like US Patent 11154549 Opioid compositions resistant to overdose and abuse
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.